Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

BACKGROUND: This Phase 1 dose-escalation/expansion study assessed safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in advanced solid tumours. METHODS: Eligible patients received increasing sapanisertib doses once daily (QD; 31 patients), once weekly (QW; 30...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., Burris, Howard A.
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686313/
https://ncbi.nlm.nih.gov/pubmed/32913286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01041-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы